Daily Endocrinology Research Analysis
Three impactful endocrinology papers stand out today: a multicenter Lancet Diabetes & Endocrinology study introduces and validates a practical diagnostic score to distinguish arginine vasopressin deficiency (central diabetes insipidus) from primary polydipsia, enabling stepwise diagnosis in most patients. A Diabetes Care cohort shows that adolescent hyperglycemia and insulin resistance predict progressive left ventricular remodeling, largely mediated by fat mass. A JCI Insight mechanistic study
Summary
Three impactful endocrinology papers stand out today: a multicenter Lancet Diabetes & Endocrinology study introduces and validates a practical diagnostic score to distinguish arginine vasopressin deficiency (central diabetes insipidus) from primary polydipsia, enabling stepwise diagnosis in most patients. A Diabetes Care cohort shows that adolescent hyperglycemia and insulin resistance predict progressive left ventricular remodeling, largely mediated by fat mass. A JCI Insight mechanistic study reveals LRRC8 volume-regulated chloride channel complexes as key sensors of β-cell swelling that couple to insulin secretion.
Research Themes
- Practical diagnostic algorithms in endocrinology
- Cardiometabolic risk trajectories from adolescence
- Mechanistic coupling of cell volume to insulin secretion
Selected Articles
1. A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies.
Two prospective multicenter cohorts (n=299) derived and validated a stepwise diagnostic pathway using basal sodium, copeptin, and clinical features. In validation, sodium >145 mmol/L ruled in AVP deficiency with 100% specificity; sodium <135 mmol/L or copeptin >5.6 pmol/L ruled in primary polydipsia with 100% specificity. The score achieved AUC 0.91 and 86% overall accuracy, enabling diagnosis in 75% of patients without dynamic testing.
Impact: This work fills a critical diagnostic gap by providing a validated, simple score that can rapidly classify polyuria-polydipsia syndromes and reduce reliance on burdensome dynamic tests.
Clinical Implications: Use basal sodium and copeptin first; apply the score thresholds (>461 strongly favors AVP deficiency, <415 favors primary polydipsia) to guide early management and minimize dynamic testing. Laboratories should ensure copeptin availability and standardized sodium/osmolality reporting.
Key Findings
- In validation, plasma sodium >145 mmol/L identified AVP deficiency with 100% specificity; sodium <135 mmol/L or copeptin >5.6 pmol/L identified primary polydipsia with 100% specificity.
- The diagnostic score achieved AUC 0.91 and 86% overall accuracy at a cutoff of >441 points.
- High-specificity cutoffs (<415 for primary polydipsia; >461 for AVP deficiency) each yielded 93% specificity, and the stepwise approach enabled diagnosis in 75% of 299 patients.
Methodological Strengths
- Two independent international multicenter prospective cohorts with external validation
- Use of a reference standard (hypertonic saline test) and prespecified ROC-based thresholds
Limitations
- Non-randomized diagnostic design; potential spectrum and referral bias from tertiary centers
- Implementation depends on copeptin assay availability and may require calibration across laboratories
Future Directions: Prospective implementation studies to assess time-to-diagnosis, patient outcomes, and healthcare utilization; cost-effectiveness analyses; adaptation to settings without copeptin via alternative biomarkers.
BACKGROUND: Distinguishing arginine vasopressin deficiency (central diabetes insipidus) from primary polydipsia is challenging. There is no validated initial laboratory assessment or diagnostic score to rule-in or rule-out arginine vasopressin deficiency during the first consultation. Therefore, this study aimed to evaluate the diagnostic potential of basal laboratory parameters and to develop a practical diagnostic score. METHODS: Data from two international multicentre studies of patients with arginine vasopressin deficiency and primary polydipsia undergoing the hypertonic sali
2. Persistent Hyperglycemia and Insulin Resistance With the Risk of Worsening Cardiac Damage in Adolescents: A 7-Year Longitudinal Study of the ALSPAC Birth Cohort.
In 1,595 adolescents followed for 7 years, LV hypertrophy rose from 2.4% to 7.1%. Higher fasting glucose and HOMA-IR independently predicted increases in LV mass index; persistent hyperglycemia (≥5.6 and ≥6.1 mmol/L) increased the odds of worsening LV hypertrophy (OR 1.46 and 3.10). Mediation analysis showed 62% of the IR–LV mass link was explained by fat mass.
Impact: This study links adolescent dysglycemia and insulin resistance to early cardiac remodeling, quantifies risk thresholds, and identifies adiposity as a major mediator, informing early prevention targets.
Clinical Implications: Screen adolescents with persistent fasting hyperglycemia or elevated HOMA-IR for cardiometabolic risk; prioritize interventions that reduce adiposity and insulin resistance (nutrition, physical activity, sleep). Consider risk-stratified cardiac monitoring in high-risk youth.
Key Findings
- LV hypertrophy prevalence increased from 2.4% to 7.1% over 7 years.
- Each 1 mmol/L increase in fasting glucose (β 0.37 g/m2.7) and 1-unit increase in HOMA-IR (β 1.10 g/m2.7) independently associated with higher LVMI2.7.
- Persistent hyperglycemia at ≥5.6 and ≥6.1 mmol/L increased odds of worsening LV hypertrophy (OR 1.46 and 3.10), with 62% of the IR–LV mass association mediated by increased fat mass.
Methodological Strengths
- Prospective longitudinal design with repeated echocardiography and metabolic measures
- Mediation analysis quantifying the role of adiposity in cardiometabolic remodeling
Limitations
- Observational design limits causal inference; residual confounding possible
- Cohort from a single country may limit generalizability; reliance on HOMA-IR rather than clamp
Future Directions: Intervention trials targeting insulin resistance and adiposity in adolescents to test reversal or prevention of cardiac remodeling; extend to diverse populations and incorporate continuous glucose monitoring and cardiac MRI.
OBJECTIVE: Insulin resistance (IR) and dysglycemia can induce cardiac remodeling in adulthood, but little evidence exists with respect to cardiac remodeling in youth with and without evidence of new-onset glucose metabolic alterations. This study investigated whether changes in metabolic status from adolescence to young adulthood are associated with the risk of progressive cardiac remodeling and examined potential mechanistic pathways. RESEARCH DESIGN AND METHODS: From the Avon Longitudinal Study of Parents and Children (ALSPAC), U.K. cohort, 1,595 adolescents, mean (SD) age 17.7 (0.4) years, who had data on fasting plasma glucose and insulin levels, and echocardiography left ventricular (LV) mass indexed for height raised to the power of 2.7 (LVMI2.7) and in whom these factors repeatedly were measured at a clinic visit when they were aged 24 years were included. HOMA-IR was computed, hyperglycemia was defined as glucose concentration of ≥5.6 mmol/L and ≥6.1 mmol/L, and LV hypertrophy was defined as LVMI2.7 ≥51g/m2.7. RESULTS: The prevalence of LV hypertrophy increased from 2.4% at baseline to 7.1% at follow-up. Each unit increase of glucose (β = 0.37 g/m2.7 [95% CI 0.23-0.52]; P < 0.001) and HOMA-IR (1.10 g/m2.7 [0.63-1.57]; P < 0.001) was independently associated with increased LVMI2.7 over 7 years. Persistent hyperglycemia of 5.6 mmol/L and 6.1 mmol/L was associated with higher odds (odds ratio [OR] 1.46 [95% CI 1.35-1.47], P < 0.001; and 3.10 [95% CI 1.19-8.08], P = 0.021, respectively) of worsening LV hypertrophy over 7 years. Increased fat mass (62% mediation) significantly mediated the association of increased HOMA-IR with increased LVMI2.7. CONCLUSIONS: Persistent adolescent hyperglycemia and worsening IR were associated with the risk of worsening structural and functional cardiac damage, and these were largely explained by increased fat mass.
3. LRRC8 channel complexes counterbalance KATP channels to mediate swell-secretion coupling in mouse pancreatic β cells.
β-cell swelling is a physiologic signal for insulin release sensed by LRRC8 chloride channel complexes. Hypertonicity blunted GSIS by preventing swelling; hypotonicity alone raised intracellular Ca2+ and secretion independent of KATP closure. Bumetanide reduced hypotonicity-induced secretion by lowering intracellular Cl−, and β-cell Lrrc8a knockout abolished GKA50-induced secretion, establishing LRRC8-mediated swell–secretion coupling.
Impact: This study uncovers a previously underappreciated swell–secretion mechanism in β cells via LRRC8 complexes, expanding the canonical KATP-centric model and revealing therapeutic targets and drug–ion transport interactions affecting insulin secretion.
Clinical Implications: Agents that alter cellular hydration or Cl− handling (e.g., NKCC1 inhibitors) may modulate insulin secretion. LRRC8 pathways could be explored as targets to fine-tune β-cell responsiveness in diabetes; caution may be warranted with diuretics affecting β-cell Cl− gradients.
Key Findings
- Hypertonic perfusion (360–380 mOsm) dose-dependently impaired GSIS by counteracting β-cell swelling.
- Hypotonic perfusate alone increased intracellular Ca2+ and triggered insulin secretion independent of glucose or KATP closure.
- Bumetanide (NKCC1 inhibition) reduced hypotonicity-induced insulin secretion, and β-cell–targeted Lrrc8a knockout abolished GKA50-induced secretion.
Methodological Strengths
- Convergent evidence from osmotic manipulation, pharmacologic inhibition, and β-cell–specific genetic knockout
- Direct functional readouts (intracellular Ca2+, insulin secretion) linking LRRC8 activity to secretion
Limitations
- Findings are primarily in mouse islets; human translatability requires validation
- In vitro perfusion conditions may not fully recapitulate in vivo β-cell microenvironment
Future Directions: Validate LRRC8-dependent swell–secretion in human islets, map molecular interactors, and test pharmacologic modulators in vivo; assess interactions with commonly used diuretics and metabolic drugs.
Insulin secretion from pancreatic β cells is initiated by membrane potential depolarization, followed by activation of voltage-gated Ca2+ channels to trigger Ca2+-mediated insulin vesicle fusion with the β cell plasma membrane. Here, we show that β cell swelling associated with glucose metabolism was sensed by LRRC8 channel complexes and contributed to insulin secretion. Hypertonic perfusate (360-380 mOsm) dose dependently impaired glucose-stimulated insulin secretion by counteracting β cell swelling. Hypotonic perfusate alone, independent of glucose stimulation or KATP channel closure, was sufficient to increase β cell intracellular Ca2+ and trigger insulin secretion. Inhibition of sodium-potassium-chloride cotransporter-1 with bumetanide, which diminished the intracellular Cl- concentration in β cells and consequently reduced Cl- efflux via LRRC8 channel complexes, also significantly reduced hypotonic-stimulated insulin secretion. Finally, stimulation of insulin secretion by the glucokinase activator GKA50, which is known to induce β cell swelling, was entirely suppressed in β cell-targeted Lrrc8a KO islets. These data support a model wherein the LRRC8 channel complex senses β cell swelling triggered by glucose metabolism and regulates β cell insulin secretion through activation of LRRC8-mediated Cl- efflux.